The for-profit joint venture, named Avobis Bio, will combine Mayo Clinic’s cell therapy and clinical expertise with Gore’s decades of experience creating and commercializing biopharmaceutical products and medical devices. Gore is perhaps best known as the developer of Gore-Tex fabric.
Avobis Bio launched with a focus on developing a stem cell-based regenerative treatment for perianal fistulas, a condition associated with Crohn’s disease that has few existing treatment options and can lead to life-threatening complications. A phase 1 clinical trial led by Mayo Clinic researchers and Gore materials science experts has already produced promising results: More than 75 percent of patients experienced healing after one year of treatment, according to the announcement.
More articles on innovation:
U of Texas to offer graduate degree for human-centered healthcare design
90% of US ‘innovation sector’ growth centered in 5 cities
Houston Methodist’s Dr. Roberta Schwartz on the ‘struggle’ of balancing data privacy with innovation: ‘It comes with friction’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
